GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Price-to-Free-Cash-Flow

LivaNova (LivaNova) Price-to-Free-Cash-Flow

: 71.34 (As of Today)
View and export this data going back to 1993. Start your Free Trial

As of today (2024-04-20), LivaNova's share price is $52.295. LivaNova's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.73. Hence, LivaNova's Price-to-Free-Cash-Flow Ratio for today is 71.34.

The historical rank and industry rank for LivaNova's Price-to-Free-Cash-Flow or its related term are showing as below:

LIVN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.38   Med: 47.57   Max: 370.04
Current: 71.38

During the past 13 years, LivaNova's highest Price-to-Free-Cash-Flow Ratio was 370.04. The lowest was 17.38. And the median was 47.57.

LIVN's Price-to-Free-Cash-Flow is ranked worse than
78.93% of 337 companies
in the Medical Devices & Instruments industry
Industry Median: 31.21 vs LIVN: 71.38

LivaNova's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.75. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.73.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of LivaNova was -9.20% per year.

During the past 13 years, LivaNova's highest 3-Year average Free Cash Flow per Share Growth Rate was 42.30% per year. The lowest was -183.10% per year. And the median was -3.10% per year.


LivaNova Price-to-Free-Cash-Flow Historical Data

The historical data trend for LivaNova's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 57.44 68.40 70.20

LivaNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.40 64.85 95.59 332.58 70.20

Competitive Comparison

For the Medical Devices subindustry, LivaNova's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LivaNova Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where LivaNova's Price-to-Free-Cash-Flow falls into.



LivaNova Price-to-Free-Cash-Flow Calculation

LivaNova's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=52.295/0.733
=71.34

LivaNova's Share Price of today is $52.295.
LivaNova's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

LivaNova  (NAS:LIVN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


LivaNova Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of LivaNova's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova (LivaNova) Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Executives
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck officer: Chief Human Resources Officer 20 EASTBOURNE TERRACE, LONDON X0 W2 6LG

LivaNova (LivaNova) Headlines